Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,netReceivables,inventory,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,changeToNetincome,capitalExpenditures,netBorrowings,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,gmtOffSetMilliseconds,esgPopulated,tradeable,currency,marketState,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,shortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchangeDataDelayedBy,exchange,priceHint,market,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 14, 2021) 4","Short Ratio (Jul 14, 2021) 4","Short % of Float (Jul 14, 2021) 4","Short % of Shares Outstanding (Jul 14, 2021) 4","Shares Short (prior month Jun 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry,address2
t0,HRTX,196225000,101829000,,,-52614000,,-52614000,24809000,-27305000,-52114000,-52114000,,-600000,,,,0,20018000,72132000,47323000,-500000,,-52614000,-52614000,1640552000,114707000,196225000,2756000,310932000,914000,-1445362000,121000,346000,59739000,100917000,121000,38298000,272288000,106727000,38525000,42629000,1689000,-3558000.0,1164000.0,-4344000.0,883000.0,-5944000.0,883000.0,-45399000.0,-41938000.0,739000.0,-724000.0,3325000.0,11614000.0,-786000.0,,171371000,en-US,US,EQUITY,True,Delayed Quote,1.3710356,11.57 - 11.895,11.67,0.0,0.0,12,18,finmb_24366,NasdaqCM,"Heron Therapeutics, Inc.",USD,1357598,1175071,1.7299995,0.17128707,10.1 - 22.4,-10.57,-0.47187498,10.1,22.4,1620635406,1635937140,1636372800,-14400000,False,False,USD,PRE,-2.508,-1.03,-2.44,-4.8483605,2.147,11.879429,-0.04942894,-0.0041608852,15.032029,-3.2020292,-0.21301377,1204637056,-11.485437,5.5100136,15,America/New_York,EDT,"Heron Therapeutics, Inc.",11.83,1630526402,0.15999985,11.68,11.895,11.57,1013960,0,NCM,2,us_market,1.38,,,22.4,10.1,11.88,15.03,1.36M,1.18M,101.83M,,90M,0.14%,91.62%,24.25M,16.14,27.24%,23.81%,24.05M,,,,,,0.00%,,,1:20,"Jan 12, 2014","Dec 30, 2020","Mar 30, 2021",-274.23%,-266.58%,-35.12%,-81.29%,83.26M,0.92,-21.20%,-120.88M,-218.98M,-228.31M,-2.51,,166.47M,1.63,24.43M,12.45,2.70,2.15,-193.82M,-111.95M,Value,92121,Healthcare,223,9,3,"Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing HTX-011, an investigational, dual-acting, and fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam, which is in Phase III clinical trials for pain management; and HTX-034, which is in Phase Ib/II clinical trials for postoperative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.",San Diego,858 251 4400,CA,1,1609372800,1625097600,7,United States,http://www.herontx.com,86400,4,4242 Campus Point Court,Biotechnology,Suite 200
t-1,HRTX,236492000,101829000,,,-62281000,,-62281000,23656000,-32040000,-55696000,-55696000,,-601000,,,,0,20605000,76301000,52645000,-6585000,,-62281000,-62281000,1628070000,117064000,236492000,2704000,353556000,913000,-1392748000,257000,346000,105138000,102503000,257000,39014000,314196000,103353000,41850000,41905000,525000,59283000.0,-11542000.0,56789000.0,5762000.0,10586000.0,5736000.0,9997000.0,-52554000.0,712000.0,844000.0,-8196000.0,16907000.0,-2494000.0,26000.0,211693000,en-US,US,EQUITY,True,Delayed Quote,1.3710356,11.57 - 11.895,11.67,0.0,0.0,12,18,finmb_24366,NasdaqCM,"Heron Therapeutics, Inc.",USD,1357598,1175071,1.7299995,0.17128707,10.1 - 22.4,-10.57,-0.47187498,10.1,22.4,1620635406,1635937140,1636372800,-14400000,False,False,USD,PRE,-2.508,-1.03,-2.44,-4.8483605,2.147,11.879429,-0.04942894,-0.0041608852,15.032029,-3.2020292,-0.21301377,1204637056,-11.485437,5.5100136,15,America/New_York,EDT,"Heron Therapeutics, Inc.",11.83,1630526402,0.15999985,11.68,11.895,11.57,1013960,0,NCM,2,us_market,1.38,,,22.4,10.1,11.88,15.03,1.36M,1.18M,101.83M,,90M,0.14%,91.62%,24.25M,16.14,27.24%,23.81%,24.05M,,,,,,0.00%,,,1:20,"Jan 12, 2014","Dec 30, 2020","Mar 30, 2021",-274.23%,-266.58%,-35.12%,-81.29%,83.26M,0.92,-21.20%,-120.88M,-218.98M,-228.31M,-2.51,,166.47M,1.63,24.43M,12.45,2.70,2.15,-193.82M,-111.95M,Value,92121,Healthcare,223,9,3,"Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing HTX-011, an investigational, dual-acting, and fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam, which is in Phase III clinical trials for pain management; and HTX-034, which is in Phase Ib/II clinical trials for postoperative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.",San Diego,858 251 4400,CA,1,1609372800,1625097600,7,United States,http://www.herontx.com,86400,4,4242 Campus Point Court,Biotechnology,Suite 200
t-2,HRTX,277147000,101829000,,,-58228000,,-58228000,21997000,-36387000,-58384000,-58384000,,-500000,,,,0,19965000,78349000,56352000,156000,,-58228000,-58228000,1606165000,112876000,277147000,2720000,390023000,909000,-1330467000,540000,346000,95141000,97578000,540000,38682000,350995000,163005000,33654000,42749000,12067000,56575000.0,-6391000.0,55943000.0,524000.0,7663000.0,524000.0,14413000.0,-42054000.0,769000.0,-1307000.0,3848000.0,11224000.0,-632000.0,26000.0,253417000,en-US,US,EQUITY,True,Delayed Quote,1.3710356,11.57 - 11.895,11.67,0.0,0.0,12,18,finmb_24366,NasdaqCM,"Heron Therapeutics, Inc.",USD,1357598,1175071,1.7299995,0.17128707,10.1 - 22.4,-10.57,-0.47187498,10.1,22.4,1620635406,1635937140,1636372800,-14400000,False,False,USD,PRE,-2.508,-1.03,-2.44,-4.8483605,2.147,11.879429,-0.04942894,-0.0041608852,15.032029,-3.2020292,-0.21301377,1204637056,-11.485437,5.5100136,15,America/New_York,EDT,"Heron Therapeutics, Inc.",11.83,1630526402,0.15999985,11.68,11.895,11.57,1013960,0,NCM,2,us_market,1.38,,,22.4,10.1,11.88,15.03,1.36M,1.18M,101.83M,,90M,0.14%,91.62%,24.25M,16.14,27.24%,23.81%,24.05M,,,,,,0.00%,,,1:20,"Jan 12, 2014","Dec 30, 2020","Mar 30, 2021",-274.23%,-266.58%,-35.12%,-81.29%,83.26M,0.92,-21.20%,-120.88M,-218.98M,-228.31M,-2.51,,166.47M,1.63,24.43M,12.45,2.70,2.15,-193.82M,-111.95M,Value,92121,Healthcare,223,9,3,"Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing HTX-011, an investigational, dual-acting, and fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam, which is in Phase III clinical trials for pain management; and HTX-034, which is in Phase Ib/II clinical trials for postoperative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.",San Diego,858 251 4400,CA,1,1609372800,1625097600,7,United States,http://www.herontx.com,86400,4,4242 Campus Point Court,Biotechnology,Suite 200
t-3,HRTX,324058000,101829000,,,-55190000,,-55190000,25408000,-30341000,-55749000,-55749000,,-400000,,,,0,22668000,78417000,53009000,559000,,-55190000,-55190000,1594436000,108663000,324058000,2633000,432721000,908000,-1272239000,953000,346000,80728000,92651000,953000,39480000,392895000,220114000,37502000,41442000,18458000,33157000.0,6896000.0,32408000.0,2312000.0,-11954000.0,2312000.0,-22557000.0,-57277000.0,745000.0,-6593000.0,-2691000.0,11175000.0,-749000.0,26000.0,300244000,en-US,US,EQUITY,True,Delayed Quote,1.3710356,11.57 - 11.895,11.67,0.0,0.0,12,18,finmb_24366,NasdaqCM,"Heron Therapeutics, Inc.",USD,1357598,1175071,1.7299995,0.17128707,10.1 - 22.4,-10.57,-0.47187498,10.1,22.4,1620635406,1635937140,1636372800,-14400000,False,False,USD,PRE,-2.508,-1.03,-2.44,-4.8483605,2.147,11.879429,-0.04942894,-0.0041608852,15.032029,-3.2020292,-0.21301377,1204637056,-11.485437,5.5100136,15,America/New_York,EDT,"Heron Therapeutics, Inc.",11.83,1630526402,0.15999985,11.68,11.895,11.57,1013960,0,NCM,2,us_market,1.38,,,22.4,10.1,11.88,15.03,1.36M,1.18M,101.83M,,90M,0.14%,91.62%,24.25M,16.14,27.24%,23.81%,24.05M,,,,,,0.00%,,,1:20,"Jan 12, 2014","Dec 30, 2020","Mar 30, 2021",-274.23%,-266.58%,-35.12%,-81.29%,83.26M,0.92,-21.20%,-120.88M,-218.98M,-228.31M,-2.51,,166.47M,1.63,24.43M,12.45,2.70,2.15,-193.82M,-111.95M,Value,92121,Healthcare,223,9,3,"Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing HTX-011, an investigational, dual-acting, and fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam, which is in Phase III clinical trials for pain management; and HTX-034, which is in Phase Ib/II clinical trials for postoperative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.",San Diego,858 251 4400,CA,1,1609372800,1625097600,7,United States,http://www.herontx.com,86400,4,4242 Campus Point Court,Biotechnology,Suite 200
